Japanese Researchers Discover Drug Target For Osteoporosis, Rheumatoid Arthritis
This article was originally published in PharmAsia News
Executive Summary
A team led by osteo-immunology professor, Hiroshi Takayanagi, of Tokyo Medical and Dental University, found two enzymes in osteoclastic cells that cause osteoporosis and rheumatoid arthritis. If inhibitors inside the human body can be developed to constrain the enzymes, the research could lead to the discovery of treatments for the diseases. By analyzing DNA of the cells, the team found that the enzyme Btk and Tec are responsible for building the cells. After compounds that constrain the two enzymes were given to a mouse, symptoms of osteoporosis and rheumatoid arthritis improved. (Click here for more - Japanese language
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.